Overexpression of H19 was found to inhibit TGF-β1-induced HSC proliferation, suggesting therapeutic potential by targeting MeCP2 and its downstream effectors, including H19 and IGF1R, to mitigate liver fibrosis. This evidence concerns the gene H19 and Hepatic fibrosis.